Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10 yr after diagnosis: results from a population-based study using the PROFILES registry-Reference-Cited by-同舟云学术

Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10 yr after diagnosis: results from a population-based study using the PROFILES registry

Published:2012-08-01 Issue:4 Volume:89 Page:311-319
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Mols Floortje,Oerlemans Simone,Vos Allert H.¹,Koster Ad²,Verelst Silvia³,Sonneveld Pieter³,Poll-Franse Lonneke V.

Affiliation:

1. Department of internal medicine; Bernhoven hospital; Oss; The Netherlands

2. Department of internal medicine; VieCurie hospital; Venlo/Venray; The Netherlands

3. Department of hematology; Erasmus University Medical Center; Rotterdam; The Netherlands

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-0609.2012.01831.x/fullpdf

Reference31 articles.

1. Improved survival among younger but not among older patients with Multiple Myeloma in the Netherlands, a population-based study since 1989;Schaapveld;Eur J Cancer,2010

2. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma;Jagannath;Br J Haematol,2005

3. Treatment of myeloma in patients not eligible for transplantation;Jagannath;Curr Treat Options Oncol,2005

4. Recent major improvement in long-term survival of younger patients with multiple myeloma;Brenner;Blood,2008

Cited by 105 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. „Patient-reported outcomes“ in medizinischen Registern;Die Onkologie;2024-03-01

2. Adhesive capsaicin 8% patch for improved control of pain caused by chemotherapy-induced peripheral neuropathy in patients with multiple myeloma: A single-centre, seven-case series;Journal of Oncology Pharmacy Practice;2024-02-28

3. Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study;Clinical Lymphoma Myeloma and Leukemia;2023-11

4. Assessment of the psychometric properties of the Spanish version of EORTC QLQ-MY20 and evaluation of health-related quality of Life outcomes in patients with relapsed and/or refractory multiple myeloma in the real-world setting in Spain: results from the CharisMMa study;Leukemia & Lymphoma;2023-08-04

5. A patient survey indicates quality of life and progression-free survival as equally important outcome measures in multiple myeloma clinical trials;Journal of Cancer Research and Clinical Oncology;2023-07-19